Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT06463665 2026-06-04

VIRO-25

142 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT06511726 2026-06-04

CATPCC-01

29 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07628062 2026-06-04

Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation

70 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04753879 2026-06-03

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

38 enrolled

Pancreatic Neoplasms

NCT06096844 2026-06-03

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

304 enrolled

Lung Neoplasms

NCT06770452 2026-06-03

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

133 enrolled

Phase 2/3 Active not recruiting

Pancreatic Neoplasms

NCT07076121 2026-06-03

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

470 enrolled

Pancreatic Neoplasms

NCT07491445 2026-06-03

RASolute 303

900 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT04104672 2026-06-02

ARC-8

196 enrolled

Pancreatic Neoplasms

NCT06018337 2026-06-02

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

541 enrolled

Breast Neoplasms

NCT06608927 2026-06-02

PRISM-1

610 enrolled

Pancreatic Neoplasms

NCT06625320 2026-06-02

RASolute 302

500 enrolled

Pancreatic Neoplasms

NCT06917079 2026-06-02

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Phase 1 Recruiting

665 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT07621718 2026-06-02

RASolute 305

670 enrolled

Pancreatic Neoplasms

NCT04594772 2026-06-01

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

32 enrolled

Pancreatic Neoplasms

NCT05633667 2026-06-01

VELOCITY-Lung

192 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06360354 2026-06-01

MTAPESTRY 103

120 enrolled

Neoplasms, Pancreatic Neoplasms

NCT06422143 2026-06-01

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

851 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07060807 2026-06-01

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

1,000 enrolled

Breast Neoplasms

NCT07618793 2026-06-01

Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma

60 enrolled

Pathologic Complete Response, Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04310007 2026-05-29

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

117 enrolled

Lung Neoplasms

NCT06841354 2026-05-29

TroFuse-011

1,000 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06926868 2026-05-29

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07492680 2026-05-29

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

CNSDermatologicGastrointestinal

260 enrolled

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

NCT06361888 2026-05-28

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

502 enrolled

Pancreatic Neoplasms

NCT07024615 2026-05-28

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Phase 1 Recruiting

25 enrolled

Pancreatic Ductal Adenocarcinoma

NCT07221474 2026-05-28

INTerpath-13

180 enrolled

Squamous Non-small Cell Lung Cancer

NCT07223047 2026-05-28

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Phase 1/2 Recruiting

252 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07452601 2026-05-28

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

90 enrolled

Esophageal Squamous Cell Carcinoma

NCT07610629 2026-05-28

RA-A-NP

50 enrolled

Gastric Adenocarcinoma

NCT03520686 2026-05-26

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Terminated

102 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06731907 2026-05-26

MK-3475-01G

90 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06312176 2026-05-22

MK-2870-010

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1 Terminated

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06998940 2026-05-22

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

94 enrolled

Pancreatic Neoplasms

NCT07173751 2026-05-22

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

558 enrolled

Breast Neoplasms

NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

182 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04015778 2026-05-20

A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

316 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04768075 2026-05-20

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Phase 3 Completed

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07365319 2026-05-20

TeLuRide-008

750 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03530397 2026-05-19

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

400 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT05431270 2026-05-19

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

40 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07280377 2026-05-19

GOBLET

122 enrolled

Anal Cancer Metastatic

NCT07595770 2026-05-19

ANCRE

37 enrolled

Esophageal Squamous Cell Carcinoma

NCT05685602 2026-05-18

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Phase 1 Suspended

43 enrolled

Pancreatic Neoplasms

NCT07063745 2026-05-18

MountainTAP-29

590 enrolled

Lung Neoplasms

NCT05374512 2026-05-15

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

644 enrolled 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT06591650 2026-05-14

GCND